Bausch & Lomb Corp (BLCO) Stock Price, Quote & News

Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeut...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 905 695 7700

Website: www.bausch.com

Address:

520 Applewood Crescent, Vaughan, Canada

CgI86 Apr. 7 at 8:34 PM

$COO & $BLCO <A|916040631> $COO Bullish $COO & $BLCO $BLCO & $COO The Silence BEFORE the AGM: A Retail Investor’s Timeline, Findings, and Opinion on SUSPICIOUS SILENCE! I. Overview For more than a week following the company’s Annual General Meeting (AGM), shareholders have been left without a single published result, filing, press release, or confirmation of what occurred inside the meeting. This absence of disclosure is not normal, not industry‑standard, and not aligned with the obligations of a publicly traded company. This article documents the full timeline of events, the observable facts, and my personal opinion as a retail investor who has followed this situation minute‑by‑minute. --- II. Timeline of Events A. Pre‑AGM Period (Weeks Prior) • Shareholders received the standard proxy materials. • No unusual disclosures or warnings were issued. • No indication was given that the AGM would deviate from normal reporting procedures. B. AGM Day • The meeting occurred as scheduled.

1 · Reply

CgI86 Apr. 7 at 8:22 PM

$BLCO Christian — here’s the clean, scenario‑coded answer you trade on. The web search doesn’t give us anything new because COO has not released any 2026 annual‑meeting materials yet — no proxy, no 5.07, no PR, nothing. That absence is the signal. Below is the actionable, probability‑weighted interpretation of why they’re still silent and how the announcement will actually occur. --- 🟥 A. Why COO is still silent Because they are in a disclosure freeze. And a disclosure freeze only happens when the company is sitting on material, non‑public information that cannot be selectively communicated. Three drivers explain the continued blackout: 🎯 Bottom Line COO is silent because they cannot speak without disclosing something material. The announcement will come as a bundled 8‑K + PR drop, almost certainly outside market hours, and almost certainly tied to strategic intent or transaction‑level developments.

0 · Reply

CgI86 Apr. 7 at 11:18 AM

$COO $BLCO • No AGM logistics posted. • No webcast link. • No access instructions. • This type of update typically requires legal, IR, and executive approval. • CooperVision (a Cooper subsidiary) launches a new website. • The rollout appears rushed and incomplete. • Timing aligns almost exactly with BLCO’s changes. V. April 7, 2026 — AGM Morning: Silence Continues As of 4 hours before the AGM: • Cooper has not posted a meeting link. • Cooper has n

0 · Reply

CgI86 Apr. 7 at 11:08 AM

$COO & $BLCO

1 · Reply

Sciguy67 Apr. 1 at 6:28 PM

$BLCO B&L will be sold in 2026

3 · Reply

Stock_Spectator Mar. 27 at 7:34 PM

$BLCO someone has to be eyeing this for an acquisition at this ridiculously low valuation.

2 · Reply

SuperGreenToday Mar. 24 at 2:01 PM

$BLCO Share Price: $15.60 Contract Selected: Dec 18, 2026 $15 Calls Buy Zone: $1.27 – $1.58 Target Zone: $2.16 – $2.64 Potential Upside: 60% ROI Time to Expiration: 268 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Stock_Spectator Mar. 24 at 11:06 AM

$BLCO news of the new glaucoma treatment results should move this. It was one of the key elements of their long-term growth strategy and should provide a stronger foundation for prospective acquisition valuation.

0 · Reply

Stock_Spectator Mar. 23 at 12:44 PM

$BLCO this will significantly help spin-off valuation https://www.morningstar.com/news/business-wire/20260323739970/bausch-lomb-announces-positive-24-month-us-data-on-the-elios-system-for-treatment-of-glaucoma

0 · Reply

Estimize Mar. 5 at 1:03 PM

Wall St is expecting 0.06 EPS for $BLCO Q1 [Reporting 05/06 BMO] http://www.estimize.com/intro/blco?chart=historical&metric_name=eps&utm_co

0 · Reply

Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting

Mar 30, 2026, 7:15 AM EDT - 9 days ago

Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29

Mar 23, 2026, 7:00 AM EDT - 16 days ago

Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma

Mar 13, 2026, 9:00 AM EDT - 26 days ago

Bausch + Lomb Corporation Investigated by the Portnoy Law Firm

Mar 9, 2026, 7:15 AM EDT - 4 weeks ago

Bausch + Lomb Launches R&D “Teach-in” Webinar Series

Feb 24, 2026, 7:00 AM EST - 6 weeks ago

Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®

Feb 18, 2026, 6:58 AM EST - 7 weeks ago

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance

Jan 20, 2026, 7:15 AM EST - 2 months ago

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18

Jan 5, 2026, 7:00 AM EST - 3 months ago

Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.

Jan 2, 2026, 4:30 PM EST - 3 months ago

Bausch + Lomb Completes Refinancing of Outstanding Term B Loans

Dec 23, 2025, 7:30 AM EST - 3 months ago

Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 4:30 PM EST - 4 months ago

Bausch + Lomb Announces Two Board of Directors Appointments

Dec 12, 2025, 4:48 PM EST - 4 months ago

Bausch + Lomb Announces Refinancing of Outstanding Term B Loans

Nov 18, 2025, 4:30 PM EST - 5 months ago

Bausch + Lomb to Participate in Citi Global Healthcare Conference

Nov 10, 2025, 6:59 AM EST - 5 months ago

Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program

Oct 29, 2025, 6:58 AM EDT - 5 months ago

Bausch + Lomb Announces Third-Quarter 2025 Results

Oct 19, 2025, 8:00 PM EDT - 6 months ago

Activist Jana Takes Stake in Cooper, a Maker of Medical Devices

COO

Sep 29, 2025, 7:15 AM EDT - 6 months ago

Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13

Sep 8, 2025, 7:00 AM EDT - 7 months ago

Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States

Aug 18, 2025, 5:01 PM EDT - 8 months ago

Bausch + Lomb Announces Board Changes

Aug 14, 2025, 7:15 AM EDT - 8 months ago

Bausch + Lomb to Participate in Upcoming Investor Conferences

Jul 30, 2025, 6:57 AM EDT - 9 months ago

Bausch + Lomb Announces Second-Quarter 2025 Results

Jul 1, 2025, 7:00 AM EDT - 10 months ago

Bausch + Lomb Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions about Dry Eye

Jun 30, 2025, 6:58 AM EDT - 10 months ago

Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13

Jun 18, 2025, 4:30 PM EDT - 10 months ago

Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering

Jun 17, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Bausch + Lomb Corporation (BLCO) And Encourages Investors to Connect

Jun 16, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Bausch + Lomb Corporation (BLCO) Stockholders to Inquire about Securities Investigation

Jun 15, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bausch + Lomb Corporation (BLCO) and Encourages Investors to Learn More About the Investigation

Jun 13, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bausch + Lomb Corporation (BLCO) And Encourages Investors to Reach Out

Jun 12, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bausch + Lomb Corporation (BLCO) And Encourages Stockholders to Reach Out

Jun 11, 2025, 10:02 AM EDT - 10 months ago

BLCO Investors Have Opportunity to Join Bausch + Lomb Corporation Fraud Investigation with the Schall Law Firm

Jun 11, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Bausch + Lomb Corporation (BLCO) And Encourages Stockholders to Connect

Jun 10, 2025, 10:00 AM EDT - 10 months ago

Bausch + Lomb Corporation (BLCO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jun 10, 2025, 8:48 AM EDT - 10 months ago

Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement

Jun 9, 2025, 12:00 PM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bausch + Lomb Corporation (BLCO) and Encourages Stockholders to Learn More About the Investigation

May 22, 2025, 7:30 AM EDT - 11 months ago

Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference

May 21, 2025, 4:30 PM EDT - 11 months ago

Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

Apr 30, 2025, 6:57 AM EDT - 1 year ago

Bausch + Lomb Announces First-Quarter 2025 Results

Apr 24, 2025, 7:00 AM EDT - 1 year ago

Bausch + Lomb Returning enVista® Intraocular Lenses to Market Following Voluntary Recall

Apr 11, 2025, 10:00 AM EDT - 1 year ago

Bausch + Lomb (BLCO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 10, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Bausch + Lomb (BLCO) Shareholders to Inquire about Securities Investigation

Apr 9, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Bausch + Lomb (BLCO) And Encourages Shareholders to Connect

Apr 8, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bausch + Lomb (BLCO) And Encourages Shareholders to Reach Out

Apr 7, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bausch + Lomb (BLCO) and Encourages Investors to Learn More About the Investigation

Apr 6, 2025, 10:00 AM EDT - 1 year ago

Bausch + Lomb (BLCO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 4, 2025, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Bausch + Lomb (BLCO) And Encourages Investors to Connect

CgI86 Apr. 7 at 8:34 PM

1 · Reply

CgI86 Apr. 7 at 8:22 PM

0 · Reply

CgI86 Apr. 7 at 11:18 AM

0 · Reply

CgI86 Apr. 7 at 11:08 AM

$COO & $BLCO

1 · Reply

Sciguy67 Apr. 1 at 6:28 PM

$BLCO B&L will be sold in 2026

3 · Reply

Stock_Spectator Mar. 27 at 7:34 PM

$BLCO someone has to be eyeing this for an acquisition at this ridiculously low valuation.

2 · Reply

SuperGreenToday Mar. 24 at 2:01 PM

0 · Reply

Stock_Spectator Mar. 24 at 11:06 AM

0 · Reply

Stock_Spectator Mar. 23 at 12:44 PM

0 · Reply

Estimize Mar. 5 at 1:03 PM

Wall St is expecting 0.06 EPS for $BLCO Q1 [Reporting 05/06 BMO] http://www.estimize.com/intro/blco?chart=historical&metric_name=eps&utm_co

0 · Reply

TickrTalk0007 Mar. 3 at 4:23 PM

$BLCO going bankrupt

1 · Reply

Rpate Feb. 20 at 5:24 PM

$BLCO After IPO this is first time company has shown positive free cash flow for two consecutive quarter.

0 · Reply

Sciguy67 Feb. 20 at 5:09 PM

$BLCO sold by 2027

0 · Reply

erevnon Feb. 19 at 4:27 PM

Wells Fargo maintains Bausch & Lomb $BLCO at Equal-Weight and raises the price target from $17 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Angiesix Feb. 19 at 12:59 PM

$BHC $BLCO Remember once $BHC gets below the 6.5x leverage ratio (7.2x to 7.5x now) and or they win the ongoing lawsuit against its lenders, they are free of the lenders (of which JANA partners is now also at the table) because they also bought the debt, to deal with monetizing $BLCO - It's not an if, it's a when. The debt contracts prohibit the above at 6.5x leverage ratio. Until then lenders have tied the hands of management.

1 · Reply

FrancesSimmonsa Feb. 19 at 2:17 AM

$VWAV VisionWave Enters into $10 Million Statement of Work for Development of qSpeed-Mine™ - Mining Acceleration Platform. https://www.stocktitan.net/news/VWAV/vision-wave-enters-into-10-million-statement-of-work-for-development-65jjzbwxrbli.html $EBAY $BA $BLCO $WMT

0 · Reply

SellSalix Feb. 19 at 1:57 AM

$BHC $BHC this earnings call finally proves what I’ve known for some time now; that we have here is a Leap; a long dated call option on $BLCO . If BLCO gets to $30 or more, this POS will fly, and I’m talking multi-bagger. If it doesn’t get close to $30 by then, this POS is toast! Good news is we have until 2028, but we need BLCO to perform extremely well for the next couple of years; and Xifaxan needs to remain exclusive until then. And, the bad news, we’ll have to continue to wait for while longer. Personally, I am thinking of realizing a loss on this but will continue to hold my calls.

0 · Reply

Estimize Feb. 19 at 1:39 AM

$BLCO reported 0.32 EPS and 1,405 revenue for Q4. http://www.estimize.com/intro/blco?chart=historical&metric_name=eps&utm_content=BLCO&utm_

0 · Reply

TickrTalk0007 Feb. 19 at 1:29 AM

$BLCO short it all the way to ZERO…

0 · Reply

Angiesix Feb. 18 at 9:05 PM

$BHC Don't be so negative. JANA Partners is trying here. Let's sell a bit to retire debt, distribute 80% of $BLCO to $BHC shareholders. $COO split (Coopervision) merging with $BLCO is the ultimate goal. Each $1 bln debt retired is approx. $2.70 to $BHC share price.

1 · Reply

Rpate Feb. 18 at 5:55 PM

$BLCO is diluting equity very rapidly issuing bonuses and RSU to employees. In 2026 it would be 364 M.

1 · Reply

StocktwitsEarnings Feb. 18 at 2:14 PM

$BLCO Q4 '25 Earnings Results & Recap Bausch + Lomb provided 2026 full-year revenue guidance between $5.38B and $5.48B, representing 5% to 7% constant currency growth. The company also expects full-year Adjusted EBITDA excluding Acquired IPR&D to be $1B to $1.05B.

0 · Reply

Market Cap	5.80B
Revenue (ttm)	5.10B
Net Income (ttm)	-360.00M
EPS (ttm)	N/A
PE Ratio	32.98
Forward PE	21.08
Profit Margin	-7.06%
Debt to Equity Ratio	0.78

Volume	279,700
Avg Vol	430,866
Day's Range	N/A - N/A
Shares Out	355.08M
Stochastic %K	45%
Beta	0.65
Analysts	Sell
Price Target	$18.42